Mitochondrial DNA has been used to investigate phylogenetic relationships and pathophysiologic roles in aging, degenerative diseases, and cancer. We investigated the prognostic usefulness of mitochondrial DNA minisatellite (mtMS) markers compared with nuclear short tandem repeat markers by evaluating the laboratory performance and clinical value of these markers in a large sample of patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT) with various simulated conditions in vitro and in serial follow-up samples. We examined the value of mtMS markers as a prognostic indicator in 100 patients with various hematologic disorders undergoing allo-HSCT, including 35 patients with longitudinal follow-up for 55 months. The mtMS markers showed high sensitivity and accuracy for the quantitative detection of chimerism compared with nuclear short tandem repeat markers, particularly in unrelated transplantation and under inappropriate sampling conditions. Longitudinal follow-up after allo-HSCT disclosed that chimerism precisely reflected the status of engraftment or relapse during the clinicopathological course. Moreover, changes in mtMS markers in recipients before allo-HSCT were associated with clinical outcomes. Our data indicate that mtMS markers have multiple functions in monitoring mixed chimerism and predicting prognosis after allo-HSCT.
INTRODUCTION
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a crucial therapeutic modality for various hematologic disorders [1, 2] . Successful allo-HSCT requires the engraftment of transplanted hematopoietic stem cells, which reestablishes normal hematologic and immunologic functions [3, 4] . Therefore, reliable methods for monitoring mixed chimerism (MC) in patients undergoing allo-HSCT have been emphasized.
Nuclear short tandem repeat (STR) markers are widely used for this purpose, because they are highly polymorphic between individuals. The STR assay produces sensitive quantitative results, with a detection limit of 1% to 3% using fluorescence-labeled primers and a capillary electrophoresis system [5, 6] . However, potential problems with the nuclear STR assay include poor precision and relatively low sensitivity, particularly when the target DNA content is low or degraded [3] .
Mitochondrial DNA (mtDNA) also has high variability and numerous polymorphisms, which have been used to examine personal identification and phylogenetic relationships. We previously reported that mtDNA minisatellite (mtMS) markers generally have higher sensitivity and accuracy compared with nuclear STR markers [7, 8] . These beneficial attributes have been applied only to small and limited sets of hematologic disorders, however, which might not represent sufficient laboratory performance, especially in inappropriately obtained specimens, or accurately reflect the clinical value of mtMS markers in quantitatively determining MC after allo-HSCT.
In the present study, we investigated the laboratory performance and clinical value of mtMS markers compared with nuclear STR markers in 100 patients undergoing allo-HSCT, including serial follow-up samples and various simulated conditions in vitro.
MATERIALS AND METHODS Diagnostic and Therapeutic Characteristics of Patients
This study prospectively enrolled 100 patients (42 males and 58 females) with bone marrow (BM) failure and various hematologic disorders who underwent allo-HSCT at Chonnam National University Hwasun Hospital between August 2006 and February 2011. The study was approved by the hospital's Institutional Review Board. After patients provided written informed consent, peripheral blood and BM samples were collected. The transplantations comprised 88 HLA-matched and 12 HLA-mismatched cases, with 57 related donors and 43 unrelated donors. The recipients ranged in age from 1 to 62 years. All had a malignant hematologic disorder, which included aplastic anemia (n ¼ 17), myelodysplastic syndrome (MDS; n ¼ 15), acute myelogenous leukemia (n ¼ 23), acute lymphoblastic leukemia (ALL; n ¼ 28), lymphoma (n ¼ 7), chronic myelogenous leukemia (n ¼ 5), hemophagocytic lymphohistiocytosis (n ¼ 4), and neuroblastoma (n ¼ 1). Patients' diagnostic and therapeutic characteristics are summarized in Supplemental Table S1 . 
Myeloablative Conditioning Regimen for SCT
The study included patients receiving reduced-intensity or conventional myeloablative conditioning before allo-HSCT. Conventional myeloablative conditioning is defined as standard high-dose radiotherapy or chemotherapy. Reduced-intensity conditioning is defined as the use of fludarabine associated with low-dose total body irradiation ( 6 Gy) or busulfan (total dose 8 mg/kg) or with other immunosuppressive or chemotherapeutic drugs, such as melphalan or cyclophosphamide [9] .
Preparation of Donor and Recipient Samples
Peripheral blood samples were obtained from the donor and recipient before allo-HSCT for the selection of informative markers. BM samples were usually obtained at 1, 2, 3, 6, 9, 12, 15, 18 , and 24 months after allo-HSCT, based on the clinical course. Cell preparation and total DNA extraction were performed according to previously published protocols. In brief, mononuclear cells collected from donor and recipient samples were separated by density-gradient centrifugation and washed twice in PBS. The final PBS suspension contained 1 Â 10 7 cells/mL. Total DNA was extracted using the QIAamp Blood Mini Kits (Qiagen, Hilden, Germany) according to the manufacturer's instructions and resuspended in TE buffer (10 mM Tris-HCl and 1 mM EDTA; pH 8.0), then quantified spectrophotometrically [8] .
Chimerism Assay Using mtMS and Nuclear STR Markers
We chose 3 mtMS markersd303 poly C, 16184 poly C, and 514 (CA) repeatdbased on our findings in a previous study [8] . We analyzed the informativeness of the mtMS markers compared with nuclear STR markers using clinical records. PCR amplification and capillary electrophoresis for nuclear STR and mtMS markers were performed following our published protocols [8] . The markers' nucleotide sequences are presented in Supplemental Table S2 .
In Vitro Mixing and Simulation Test to Determine the Sensitivity and Accuracy of Nuclear STR and mtMS Markers
We performed an in vitro mixing test to determine the sensitivity and accuracy of the mtMS and nuclear STR markers under various sample conditions. Blood cells from the donor and recipient were mixed at various ratios in donor cell proportions of 0.01, 0.03, 0.05, 0.1, 0.2, 0.3, and 0.5. The sensitivity and accuracy of mtMS and nuclear STR markers were compared in samples stored at room temperature (25 C) and at 37 C for 1, 2, 3, and 4 weeks.
Application of Both Markers to Serial Follow-Up Samples to Evaluate Clinical Values
Clinicopathological parameters evaluated included WBC count, hemoglobin (Hgb), platelet count, BM examination, and an MC assay using the nuclear STR and mtMS markers. Thirty-five of the 100 enrolled patients were followed longitudinally for clinical and pathological findings for up to 55 months (range, 3-55 months; median, 22 months).
Analysis of Clinical Characteristics According to Alteration Type of mtMS Markers
Donors and recipients were classified based on the degree of sequence alteration of mtMS markers. The complex type was defined as the presence of 3 or more copies in 303 poly C mtMS marker, and the simple type was defined as fewer than 3 copies. Clinicopathological parameters, including overall survival (OS) and relapse-free survival (RFS), were analyzed according to the simple or complex degree of alteration of the mtMS marker in both donor and recipient cells before allo-HSCT.
Statistical Analysis
The c 2 test was used to determine statistical differences in informativeness between the mtMS and nuclear STR markers. Pearson's correlation coefficient was used to determine the percent difference in quantified chimerism in the mixing test. OS was defined as the time between transplantation and death from any cause, and RFS was defined as the time between transplantation and relapse or disease progression from underlying disease. RFS and OS were estimated by the Kaplan-Meier estimator. Cox proportional hazards analysis was used to compare estimated hazard ratios (HRs) and 95% confidence intervals (CIs) for mortality and relapse in patients according to the alteration type of mtMS from the donor and recipient blood cells.
RESULTS

mtMS and Nuclear STR Markers Have Comparable Discriminative Power in the Allo-HSCT Set
Informativeness was compared in the selected mtMS markers and 6 nuclear STR markers ( Table 1 ). The D18S51 and D12S391 markers were representative of informative nuclear STR markers with high exclusion power, with informativeness of 49% and 37%, respectively. The informativeness of the 303 poly C and 514(CA) repeat mtMS markers was 48.5% and 35.0%, respectively. In particular, in the unrelated allo-HSCT sample, the mtMS markers provided greater discrimination than the nuclear STR markers: 69.8% for 303 poly C and 62.8% for 514(CA) repeat versus 46.5% for D18S51 and 44.2% for D12S391 (P ¼ .001 and .011). In contrast, in related allo-HSCT, mtMS markers showed lower discriminative power than those of the nuclear markers: 50.9% for D18S51 versus 31.6% for 303 poly C (P ¼ .006). There were no statistically significant differences between the mtMS and nuclear STR markers in terms of transplantation type (HLA-matched or -mismatched) or source ( Supplemental Tables S3 and S4 ).
mtMS Markers Have Greater Sensitivity and Accuracy than Nuclear STR Markers in Inappropriately Stored Samples
Sensitivity of the mtMS and nuclear STR markers was assessed by an in vitro mixing test. Supplemental Figure 1 shows the formula used to calculate MC values. The mtMS marker 303 poly C showed a detection limit of 1%, independent of storage temperature and duration. The nuclear STR marker D12S391 displayed a variable detection limit exceeding 1%. In samples stored for longer than 3 weeks, the D12S391 peak was not observed, even with a high proportion of donor cells (>10%). At room temperature, the calculated percentages of donor cells showed good correlation with the mixture ratio for up to 3 weeks of storage for both markers. The nuclear STR marker showed no peak or unstable results when samples were stored for longer than 2 weeks at 37 C, whereas the mtMS marker showed clear and precise peaks (Figure 1 ).
mtMS and Nuclear STR Markers Show Comparable Results in Evaluation of Chimerism Status
Data from follow-up analysis of quantitative chimerism after allo-HSCT were available in 35 patients and showed generally similar chimerism status with the 2 markers. The concordancy for complete chimerism or MC in the 2 markers was 95.1% (116 of 122 tests). Discrepancies in chimerism status were evident in only 6 patients from the serial followup samples (Figure 2A ).
mtMS Markers Precisely Reflect Engraftment or Relapse during the Clinicopathological Course
Among the 35 patients with follow-up data, 1 patient (patient 15) who was diagnosed with hemophagocytic lymphohistiocytosis and underwent unrelated BM transplantation Figure 1 . Sensitivity and accuracy of 303 polyC mtMS marker compared with nuclear STR marker under different storage conditions. The 303 poly C showed a constant 1% detection limit compared with the nuclear STR marker, which was independent of storage temperature and duration (A, B, C, and E). The nuclear STR marker showed no peak or unstable results when samples were stored for more than 2 weeks at 37 C (D), whereas the mtMS marker showed clear and precise peaks (B). on June 14, 2006, achieved well-engrafted status based on clinicopathological data, including WBC, Hgb, platelet counts, and BM study. Follow-up analysis revealed MC in approximately 40% to 60% of the donor cells using the nuclear STR markers, without complete reflection of the clinicopathological course but in approximately 30% to 70% of the donor cells using the mtMS markers, which was compatible with clinical improvement ( Figure 2B ).
Another patient (patient 68) who was diagnosed with MDS and underwent unrelated peripheral blood stem cell transplantation on February 25, 2010, achieved wellengrafted status, with hypercellular marrow noted at the initial BM study. A follow-up assay for MC found 100% donor chimerism using the nuclear STR markers. However, the mtMS markers showed MC with 2% to 3% remnant recipient cells. Subsequently, a serial follow-up study using the nuclear STR markers showed 100% donor chimerism, whereas the mtMS markers showed MC with 25.2% of the donor cells. During this clinical stage, bicytopenia persisted, and MDS finally recurred ( Figure 2C ). These findings indicate that the mtMS markers can closely reflect engraftment or relapse based on the clinicopathological course.
Patient Demographics and Characteristics According to Alteration Type of mtMS Markers and Conditioning Regimens for SCT
Patient demographic data according to mtMS alteration type in donor and recipient are summarized in Table 2 . The simple and complex groups in both donor and recipient mtMS were comparable with respect to age, sex, diagnosis, donorerecipient relationship, type of transplantation, pretransplantation conditioning regimens, and variable ANC indicates absolute neutrophil count; BMT, bone marrow transplantation; PBSCT, peripheral blood stem cell transplantation; UCBT, umbilical cord blood transplantation.
* The day after allo-HSCT with an ANC >500/mL for 3 consecutive days. y The day after allo-HSCT with a platelet count >20,000/mL for 3 consecutive days. prognostic estimates. Patient demographic data according to conditioning regimen are also summarized in Supplemental  Table S5 . The simple and complex groups were comparable in terms of all parameters except underlying hematologic disorders.
Alteration Type of mtMS Markers in Recipient Cells before Allo-HSCT Is Associated with Prognosis
Patients who received conditioning with a conventional myeloablative regimen had a greater risk of relapse (relative risk, 1.786; P ¼ .043) and lower OS and RFS (P ¼ .028) compared with those who received a reduced-intensity regimen ( Table 3 and Supplemental Table S6 ). Patients harboring BM cells with the simple type of mtMS markers before allo-HSCT had shorter OS and RFS compared with those with complex markers, especially in reducedintensity myeloablative regimens, but the difference was not statistically significant. Female recipients showed a tendency toward shorter OS and RFS compared with male recipients. Correlation with clinical outcome showed an association between length heteroplasmy complexity of mtMS markers from donor BM cells and a tendency toward increased risk of relapse and overall mortality regardless of the conditioning regimen (HR, 1.428; 95% CI, 0.777-2.624; P ¼ .252 and HR, 1.502; 95% CI, 0.777-2.903, respectively; P ¼ .226). Moreover, patients with acute leukemia, particularly ALL, harboring BM cells with the complex type of 303 poly C mtMS marker before allo-HSCT had shorter OS and RFS compared with those with the simple type (P ¼ .041) ( Figure 3) .
DISCUSSION
Monitoring the degree of engraftment is crucial to distinguish between donor and residual host hematopoietic cells in allo-HSCT, given that a quantitative determination of MC can predict engraftment or graft rejection. Nuclear STR markers have been widely used because of their high polymorphism between individuals. A previous study reported potential problems of the nuclear DNA STR markers, however, including poor precision and relatively low sensitivity, particularly in conditions involving lower content and degradation of target DNA [3] . In the present study, we investigated the laboratory performance and clinical values of mtMS markers compared with nuclear STR markers in a series of 100 patients who underwent allo-HSCT for various hematologic disorders, including 35 patients with serial follow-up samples. Various simulated conditions, including in vitro mixing and simulated samples, were used to evaluate the laboratory performance of the mtMS markers. The mtMS markers were also applied to serial follow-up samples to evaluate the recipients' clinical condition. The mtMS markers showed comparable results as the nuclear STR markers in quantitative monitoring of chimerism after allo-HSCT. Importantly, the discriminative power of the mtMS markers was superior to that of the nuclear STR markers in the unrelated allo-HSCT sample. The mtMS markers also showed higher sensitivity and accuracy than the nuclear STR markers in samples under inappropriate storage conditions. The mtMS markers precisely reflected engraftment or relapse during the recipients' clinicopathological course.
Sequence analysis of mtDNA is currently used in human forensic identification, especially in cases in which the genomic DNA is highly degraded or nonexistent owing to its abundance and inherent variability [10] . Hundreds to thousands of mtDNA copies may exist in a single cell, making recovery and sequencing easier compared with a single copy of nuclear DNA per cell. In addition, the haploid nature of mtDNA makes it easier to sequence than diploid nuclear DNA [11] , contributing to the preferential amplification and sequencing of mtDNA. Moreover, mtDNA typing is used primarily in cases in which the nuclear DNA is too degraded or cannot be recovered in sufficient quantities. These factors may explain the higher sensitivity and informativeness with mtMS markers compared with nuclear DNA markers [8] .
During the analysis of mtDNA hypervariable (HV) 1 and HV2 sequences from Korean donors, we experienced great difficulty in attempting to sequence beyond the poly-C regions and assumed that this was likely related to the high degree of length heteroplasmy in these donors [7] . In a previous study, we reported that all of our Korean subjects displayed length heteroplasmies in both 303 poly C and 16189 poly C regions in HV sequences. Marked sequence variation of mtDNA in peripheral blood cells may originate from mtDNA sequence heterogeneity of individual hematopoietic stem cells (CD34 þ cells). Thus, mtDNA sequence variations may provide a natural genetic marker for determining the contribution of individual stem cells to blood cell production for the study of hematopoiesis and stem cell trafficking [12, 13] . These observations regarding the high degree of mtMS alteration prompted us to initiate the present study.
The mtMS markers 303 poly C and 514(CA) repeat exhibited sufficient discriminative power, which were comparable with D18S51 and D12S391 frequently used in clinical samples. Although the performance of mtMS markers had been demonstrated previously in small samples of hematologic malignancy patients, it had not yet been evaluated in large clinical samples. In particular, in the unrelated allo-HSCT sample, mtMS markers provided a higher degree of discrimination than nuclear STR markers; however, mtMS markers showed lower discriminative power than the nuclear STR markers in the related allo-HSCT sample. Overall, mtMS markers were useful in clinical circumstances with an increasing unrelated HSCT approach [14] , although mtMS markers had higher similarity in related donors than in unrelated donors, owing to the strictly maternal inheritance of mtDNA.
In the in vitro mixing test, 303 poly C demonstrated a detection limit of 1% independent of storage temperature and duration. This finding might be explained by the fact that eukaryotic cells contain approximately 1000 mitochondria, with 1 to 15 mtDNA molecules per mitochondrion, and thus, a typical differentiated cell has approximately 1000-15,000 mtDNA copies. This abundant number of DNA copies makes mtMS easier to recover and type than a single nuclear copy per cell. In addition, the haploid form of mtDNA is more readily sequenced than diploid nuclear DNA, which supports preferential mtDNA amplification and sequencing [8] . Both markers were stable at room temperature for 3 weeks, but at 37 C, the nuclear STR markers were unstable in samples stored for longer than 2 weeks, whereas the mtMS markers were stable. This finding has been explained in a previous study of the imprecision of nuclear STRs with ranging from 5.4% for TPOX to 12% for D7S820 [11] . This low precision mandates a careful approach, particularly in situations with lower proportions of donor cells and various inappropriate storage conditions. Overall, we found that the mtMS markers had comparable discriminative power to nuclear STR markers but more stable performance, even in inappropriate storage conditions. The method and primer set might be applicable to other populations besides Koreans. The mtMS markers studied here should be screened when selecting informative markers before allo-HSCT, given that the informativeness of each mtMS marker might differ in disparate populations.
The mtMS markers studied here demonstrated excellent clinical performance in addition with their in vitro performance. Most follow-up data on quantitative chimerism status were similar for the nuclear STR and mtMS markers. In our follow-up analysis of 35 patients, mtMS marker status closely reflected engraftment or relapse based on the clinicopathological course.
Two representative examples among the 35 patients with follow-up data are presented. One patient who had a good prognosis with MC of approximately 40% to 60% using the nuclear markers showed MC of approximately 30% to 70% using the mtMS markers. Interestingly, the mtMS markers reflected a positive tendency correlated with this patient's clinical course. Another patient who experienced a poor clinical course had 100% donor chimerism with the nuclear STR markers. In this patient, the mtMS markers provided earlier evidence of relapse, with MC evident in 25.2% of the donor cells, compared with the nuclear STR markers. This indicates that mtMS markers can closely reflect engraftment or relapse based on the clinicopathological course.
The mitochondrion is a membrane-enclosed intracellular organelle in most eukaryotic cells that provide most of the cellular energy source and is involved in cell signaling, cellular differentiation, and apoptosis, as well as in the control of the cell cycle and cell growth. Comparing to nuclear DNA, mtDNA has a 10 to 20 fold greater susceptibility to genetic mutation, owing to its lack of intron and impaired repair capacity. mtDNA aberrations have been linked to aging, degenerative diseases, cancer, and autoimmunity. Moreover, mtDNA alterations in either the number of mtDNA copies or heteroplasmy have been related to pathogenesis in various types of cancer [15, 16] .
Interestingly, the number of mtDNA copies from healthy donors who demonstrated severe length alterations in the 303 poly C and also had 3 or more heteroplasmies exhibited a two fold decrease in mtDNA copy number compared with the number of copies isolated from donors with 2 peaks [7] . Thus, we postulate a possible relationship between the degree of mtMS alteration and clinical outcome after allo-HSCT.
Complex mtMS markers from donor BM cells indicated a worse prognostic tendency, with increased relapse and overall mortality, regardless of the pretransplantation conditioning regimen. Moreover, patients with ALL with complex type mtMS markers had shorter OS and RFS compared with those with simple type markers (P ¼ .041). This finding supports the idea that mtDNA aberrations, including mtMS alterations, play a crucial role in tumorigenesis as well as in disease progression, such as metastasis [17] . mtDNA mutations and sequence heterogeneity are frequently observed in leukemic cells, as well as in normal blood/progenitor cells [18] . Our group previously reported that normal blood cells, including BM microenvironments, exhibit a profound alteration (complex heteroplasmy) of 303 poly C mtMS, resulting in an mtDNA replication defect [7] . Profound alteration of mtMS in recipient cells and microenvironments may cause derangement of donor cell engraftment and worse prognosis (marked by shorter OS and RFS) after allo-HSCT.
Despite the aforementioned advantages of mtMS markers, we note that the observed correlation between the complexity of recipient mtDNA and transplantation outcome is preliminary, and further investigation is required. Furthermore, the universal application of mtDNA analysis may be limited, because it is unlikely to be very useful in the analysis of related transplantation chimerisms.
In conclusion, we report that the discriminative power of the mtMS markers was comparable to that of the nuclear DNA STR markers in our allo-HSCT sample. The mtMS markers showed higher sensitivity and accuracy than those of nuclear DNA STR markers in samples under inappropriate storage conditions. Moreover, the mtMS markers precisely reflected not only engraftment or relapse but also prognosis after allo-HSCT.
